Compare
Sol-Gel Technologies Ltd. vs Scynexis Inc vs CASI Pharmaceuticals, Inc. vs NewAmsterdam Pharma Co N.V.
| Latest fiscal year | Sol-Gel Technologies Ltd. SLGL | Scynexis Inc SCYX | CASI Pharmaceuticals, Inc. CASIF | NewAmsterdam Pharma Co N.V. NAMS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $19.39M | $20.60M | $20.71M | $22.50M |
| Revenue growth (YoY) | +68.0% | +449.9% | -27.4% | -50.6% |
| Gross margin | n/a | n/a | 48.6% | n/a |
| Operating margin | -38.9% | -78.0% | -217.3% | n/m |
| Net margin | -31.6% | -41.8% | -232.0% | -905.7% |
| Net income | -$6.13M | -$8.61M | -$48.06M | -$203.82M |
| EPS (Diluted) | -$2.19 | -$0.17 | -$2.59 | -$1.72 |
| Operating cash flow | $322.0K | -$5.28M | -$20.75M | -$147.78M |
| Free cash flow | $275.0K | n/a | -$20.77M | -$148.03M |
| Cash & equivalents | $11.03M | $21.26M | $5.63M | $490.00M |
| Total assets | $29.92M | $59.03M | $25.65M | $769.28M |
| Total liabilities | $7.11M | $9.65M | $62.93M | $85.85M |
| Shareholders' equity | $22.81M | $49.38M | -$37.28M | $683.43M |
| Return on year-end equity | -26.9% | -17.4% | n/a | -29.8% |
| Shares outstanding | 2.79M | 43.54M | 20.56M | 114.40M |
Revenue, most recent five fiscal years
| Fiscal year | Sol-Gel Technologies Ltd. | Scynexis Inc | CASI Pharmaceuticals, Inc. | NewAmsterdam Pharma Co N.V. |
|---|---|---|---|---|
| Latest | $19.39M Ended 2025-12-31 | $20.60M Ended 2025-12-31 | $20.71M Ended 2025-12-31 | $22.50M Ended 2025-12-31 |
| 1 year earlier | $11.54M Ended 2024-12-31 | $3.75M Ended 2024-12-31 | $28.54M Ended 2024-12-31 | $45.56M Ended 2024-12-31 |
| 2 years earlier | $1.55M Ended 2023-12-31 | $140.14M Ended 2023-12-31 | $33.88M Ended 2023-12-31 | $14.09M Ended 2023-12-31 |
| 3 years earlier | $3.88M Ended 2022-12-31 | $5.09M Ended 2022-12-31 | $43.11M Ended 2022-12-31 | $102.69M Ended 2022-12-31 |
| 4 years earlier | $31.27M Ended 2021-12-31 | $13.16M Ended 2021-12-31 | $30.17M Ended 2021-12-31 | n/a |